antibodies - CarboHyde

Pharmaceutical composition and application patent

Today’s cyclodextrin is an interesting application proposed by RemeGen Biosciences, which uses methyl-BCD to remarkably improve the pharmaceutical effect of antibody-drug conjugates. By using CDs, the ACD load can be lower, thus greatly reducing the production cost and the treatment cost of a patient.
If you are interested in similar solutions, check out Formulation development – www.carbohydesolutions.com

Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies

Apr 3, 2023Tamas SohajdaToday's cyclodextrinantibodies, excipients, protein

today’s cyclodextrin from Roquette:
Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
When subjected to light stress, adalimumab, as a model mAb, formulated in the presence of HPβCD, shows a significant decrease in protein aggregation and superior monomer and total protein recovery compared to PS 80-containing formulations. HPβCD also reduces both agitation and thermal stress-induced protein aggregation and prevents subvisible particle formation compared to PS 80.
Hailong Zhang, Shiqi Hong, Tao Peng, Kwan Hang LAM, Keat Theng Chow, Rajeev Gokhale et al

See the article here: Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies